Deck 32: Bone Marrow Transplantation

Question 1

The risk of developing graft-versus-host disease (GVHD)is strongly linked to the:

A) use of cells from an unrelated donor.
B) use of autologous bone marrow (BM)or peripheral blood stem cells (PBSCs).
C) degree of HLA mismatch between patient and donor.
D) depletion of T lymphocytes from the transplant.

Answer 1

degree of HLA mismatch between patient and donor.

Question 2

Acute lymphoblastic leukemia is treatable by stem cell transplantation.

Answer 2

True

Question 3

A major complication in patients with a bone marrow (BM)or peripheral blood stem cell (PBSC)transplant during the first month after transplantation is:

A) fungal infection.
B) cytomegalovirus (CMV)infection.
C) hepatitis B infection.
D) graft-versus-host disease (GVHD).

Answer 3

graft-versus-host disease (GVHD).

Question 4

The goal of a CD34+ antigen harvest is to infuse a minimum dose of _______ CD34+ cells of per kilogram of recipient weight.

A)
B)
C)
D)

Question 5

If bone marrow or peripheral blood stem cells (PBSCs)are not used within _______ hours,the specimen must be frozen.

A) 8
B) 12
C) 24
D) 96

Question 6

Which of the following statements about progenitor blood cells is correct?

A) They are pluripotent.
B) They are found in bone marrow and peripheral circulating blood.
C) They contain precursor cells to leukocytes and platelets.
D) All of the above.

Question 7

The minimum number of bone marrow or peripheral blood stem cells/kg patient body weight during an allogeneic transplantation is:

A) CD34+.
B) CD19+.
C) CD34+.
D) CD4+.

Question 8

Complications of bone marrow or peripheral blood stem cell (PBSC)transplantation include:

A) infection and graft-versus-host disease (GVHD).
B) acute rejection and organ damage.
C) chronic rejection and death.
D) all of the above.

Question 9

Increased cell selection and purging of grafts using cell surface membrane markers has resulted in:

A) decreased risk of tumor reinfusion into autologous recipients.
B) decreases in the amount of T cells infused in allogeneic recipients.
C) a lower incidence of GVHD.
D) both a and b

Question 10

Pretransplant evaluation of a bone marrow recipient includes:

A) HLA tissue typing.
B) disease status.
C) compatibility of donor and recipient.
D) all of the above.

Question 11

The drug that has produced the most significant breakthrough in transplantation is:

A) penicillin.
B) tetracycline.
C) cyclosporine.
D) none of the above.

Question 12

The most significant virus capable of causing complications in the late phase of bone marrow (BM)or peripheral blood stem cell (PBSC)transplantation is:

A) cytomegalovirus (CMV).
B) Epstein-Barr virus (EBV).
C) hepatitis B virus (HBV).
D) hepatitis C virus (HCV).

Question 13

Stem cell selection can be improved using the CD_______ cell surface marker.

A) 4+
B) 8+
C) 34+
D) 56+

Question 14

The most common type(s)of microorganisms found in bone marrow (BM)or peripheral blood stem cells (PBSCs)after transplantation infections is (are):

A) fungi.
B) viruses.
C) bacteria.
D) both a and c

Question 15

Toxicities and side effects associated with the infusion of cryopreserved products are mainly caused by:

A) DMSO preservative.
B) volume overload.
C) glycerol preservative.
D) both a and b

Question 16

Bone marrow is usually aspirated from the:

A) sternum.
B) anterior iliac crest.
C) posterior iliac crest.
D) either b or c

Question 17

The cryopreservatives DMSO and pentastarch are used to:

A) prevent toxicity.
B) keep cells from dehydrating.
C) prevent bacterial growth.
D) prevent fungal growth.

Question 18

Differences between donor and recipient ABO and Rh blood groups have ______ effect on marrow engraftment.

A) no
B) some
C) a major
D) an overwhelming

Question 19

Hematopoietic stem cells are:

A) uncommitted progenitor cells.
B) immature erythrocytes.
C) CD 34+ cells.
D) large,granular lymphocytes.

Question 20

PBSCs are obtained by:

A) phlebotomy.
B) apheresis.
C) leukapheresis.
D) both b and c

Question 21

Match the chemotherapeutic agents with an example or description.

Alkaloids

A)5-Fluorouracil (5-FU)
B)First agents used in bone marrow transplantation
C)Cytotoxic predominantly during M phase or G2 and M phases of cell cycle

Question 22

MATCHING
Match the transplant types with the appropriate description.

Syngeneic

A)Stem cells from identical twins
B)Marrow from a related or unrelated donor
C)Transplant of own cells

Question 23

MATCHING
Match the transplant types with the appropriate description.

Autologous

A)Stem cells from identical twins
B)Marrow from a related or unrelated donor
C)Transplant of own cells

Question 24

MATCHING
Match the transplant types with the appropriate description.

Allogeneic

A)Stem cells from identical twins
B)Marrow from a related or unrelated donor
C)Transplant of own cells

Question 25

Match the chemotherapeutic agents with an example or description.

Alkylating agents

A)5-Fluorouracil (5-FU)
B)First agents used in bone marrow transplantation
C)Cytotoxic predominantly during M phase or G2 and M phases of cell cycle

Question 26

Match the chemotherapeutic agents with an example or description.

Antimetabolites

A)5-Fluorouracil (5-FU)
B)First agents used in bone marrow transplantation
C)Cytotoxic predominantly during M phase or G2 and M phases of cell cycle

Question 27

Aplastic anemia is treatable by stem cell transplantation.

Question 28

Acute myelogenous leukemia is treatable by stem cell transplantation.